Three-Year Survival after Transcatheter Aortic Valve Replacement: Findings from the Marshfield Aortic Valve Experience (MAVE) Study
| Autor: | Sabri Elkhidir, Brooke Delgoffe, Romel Garcia-Montilla, Paul Yeung-Lai-Wah, Richard L. Berg, Sunil Pathak, Kelley P. Anderson, Deepa Soodi, Peter E. Umukoro |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Aortic valve
medicine.medical_specialty Transcatheter aortic medicine.medical_treatment Transcatheter Aortic Valve Replacement Valve replacement Risk Factors Secondary analysis medicine Humans Original Research Community and Home Care business.industry Significant difference Patient survival Aortic Valve Stenosis General Medicine medicine.disease Surgery Stenosis Treatment Outcome Aortic valve area medicine.anatomical_structure Aortic Valve Heart Valve Prosthesis business |
| Zdroj: | Clin Med Res |
| ISSN: | 1554-6179 1539-4182 |
| DOI: | 10.3121/cmr.2020.1539 |
| Popis: | Background Transcatheter aortic valve replacement (TAVR) is a rapidly evolving treatment for severe aortic stenosis. However, uncertainties exist for optimal valve selection as there are few long-term studies comparing patient survival by valve type. Objective We hypothesized that self-expandable valves (SEV) would provide a survival advantage over balloon expandable valves (BEV), as self-expandable valves continue to expand and might better accommodate to the anatomy of the aortic valve over time. Methods We examined outcomes according to valve type from a rural tertiary referral center between 2012 and 2017. Results Out of 269 patients, 77 deaths (28.6%) occurred over the study period with six deaths by 1 month post-TAVR and 37 deaths by 1 year post-TAVR. The median observation time for survivors was 21.5 months. The probability of survival at 3 years was 60.7% and 61.9% for patients who underwent treatment with SEV and BEV, respectively. There was no statistically significant difference in overall patient survival with or without adjustment for factors such as age, sex, race, and aortic valve area. Additionally, in a secondary analysis restricted to those patients treated in later years (2015-2017) survival among patients with BEV appeared superior (HR=0.456, p=0.015). Conclusion Patients who underwent TAVR at a rural medical center with an SEV showed similar survival compared to those who received a BEV. Superior survival was observed among those who received a BEV versus SEV between 2015 and 2017. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|